Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03747900
Other study ID # MuratKOSEM
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 11, 2017
Est. completion date March 30, 2018

Study information

Verified date November 2018
Source Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Stroke is a clinical picture that can result in loss of motor, sensory and cognitive functions or coma. Approximately 75% of stroke survivors develop disability and one of the causes of disability is the presence of spasticity. Effective treatment of spasticity accelerates functional recovery. Botulinum toxin type A (BTX-A) injection is a safe and effective method in the management of focal spasticity. As its effects over central and peripheral nervous system have been understood, dry needling has been recently introduced as the novel treatment of spasticity after stroke in clinical practice. Studies evaluating the efficacy of dry needling in the treatment of spasticity are limited in the literature and there is no data on the long-term efficacy of dry needling in current studies. On the other hand, the effects of dry needling when combined with other antispastic treatment modalities have not been investigated yet. In this study, the antispastic efficacy of dry needling applied with BTX-A injection was investigated.


Description:

The study was designed as a prospective, randomized, single-blind study. Patients included in the study were selected from 59 stroke patients and randomized into two groups; BTX-A injections and exercise in BTX-A Group (n=15), and BTX-A injection and exercise, additionally with dry needling in BTX-A+Dry needling Group (n=15). All patients underwent 200 U BTX-A injections in biceps brachii muscle under sonographic guidance. Patients who were included in BTX-A+Dry needling Group underwent dry needling for 4 times in total following BTX-A injection, as the first one being administered immediately after the BTX-A injection, and the remaining three with a three-day interval (3rd, 6th and 9th days after BTX-A injection). Stretching exercises for the upper extremity spastic muscles and strengthening exercises for the antagonist muscles on the hemiplegic side were applied in both groups. Patients were followed for 3 months after injection. As a result, the data obtained in this study was compatible with the results that ultrasonography (US)-guided BTX-A injection to the upper extremity together with the rehabilitation program decreased the post-stroke spasticity, improved the upper extremity motor functions, and this improvement continued until 3 months after injection. In addition, dry needling combined with BTX-A injection and performed in a total of 4 sessions with three days intervals, contributes to the antispastic effect to start earlier, to be more effective and to maintain a longer-lasting effect.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date March 30, 2018
Est. primary completion date March 30, 2018
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients with first-time stroke

- To have Modified Ashworth Scale of 2 and 3 spasticity levels in the elbow flexor muscles of the hemiplegic side

- Not having any joint pathology that would prevent passive movements of the involved elbow joint

Exclusion Criteria:

- Having a mental problem

- Presence of cooperation-orientation limitation or neglect

- Use of an oral antispastic agent

- BTX-A application in the last 3 months

- Peripheral nerve injury in the affected side upper extremity

- Wound presence in the area where the procedure will be applied

- Patients with a contraindication for BTX-A application

- Patients with needle phobia

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Botulinum Toxin Type A
200 U Botulinum toxin type A injection in the spastic biceps brachii muscle.
Combination Product:
Botulinum Toxin Type A and dry needling.
Dry needling for 4 times in total in the spastic biceps brachii muscle after the Botulinum toxin type A injection.

Locations

Country Name City State
Turkey Sultan Abdulhamid Han Training and Research Hospital Istanbul Uskudar

Sponsors (1)

Lead Sponsor Collaborator
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Modified Ashworth Scale The Modified Ashworth Scale (MAS) measures spasticity during passive soft-tissue stretching. MAS is a six-point ordinal scale for grading the resistance encountered during such passive muscle stretching. MAS grades spasticity as follows:
0: No increase in muscle tone.
1: Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is(are) moved in flexion or extension.
1+: Slight increase in muscle tone, manifested by a catch followed by minimal resistance through the remainder of the range of motion but the affected part(s) is(are) easily moved.
2: More marked increase in muscle tone through most of the range of movement, but the affected part(s) is easily moved.
3: Considerable increases in muscle tone, passive movement difficult.
4: Affected part(s) is (are) rigid in flexion or extension.
6 months.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT03908580 - MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity Phase 4
Not yet recruiting NCT04550793 - Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients
Recruiting NCT05432999 - Extracorporeal Shockwave Therapy for Spasticity in People With Spinal Cord Injury N/A
Completed NCT05687097 - Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury
Active, not recruiting NCT05562453 - Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain N/A
Recruiting NCT06214975 - EXOPULSE Mollii Suit, Motor Function & Stroke (EXOSTROKE 2) N/A
Recruiting NCT05464160 - Focal Muscular Vibration in Patients With Severe Acquired Brain Injury N/A
Completed NCT04130295 - Influence of Wearable Intensive Nerve Stimulation on Spasticity and Function in Persons With Spinal Cord Injury N/A
Recruiting NCT06070233 - Radiosurgery Treatment for Spasticity Associated With Stroke, SCI & Cerebral Palsy N/A
Completed NCT03307135 - Medical Spastic Patient Machine Interface MSPMI : Biomechanical and Electrophysiological Assessment of the Triceps Surae Spasticity N/A
Recruiting NCT05070780 - Neurophysiological Evaluation of Muscle Tone
Recruiting NCT04620707 - RGS@Home: Personalized 24/7 Home Care Post-stroke N/A
Recruiting NCT06109129 - Investıgatıon Of The Effectıveness Of The Mollıı Suıt In Chıldren Wıth Ambulatory Cerebral Palsy N/A
Enrolling by invitation NCT05598736 - Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain N/A
Completed NCT05103202 - Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
Active, not recruiting NCT05626790 - Effects of PNF and Static Stretching on Architecture and Viscoelastic Properties of Hemiplegic Elbow N/A
Recruiting NCT04904016 - Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity N/A
Withdrawn NCT05887479 - The Effect of Ultrasound-Guided Botulinum Toxin Injections on Pain, Functionality, Spasticity, and Range of Motion in Patients With Post-Stroke Upper Extremity Spasticity Phase 4
Completed NCT03442660 - Validation of the Spasticity Related Quality of Life Questionnaire N/A